Abstract: This invention relates to: (a) compounds of formula Ia (with R1, R4 to R6, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-p-hydroxylase inhibitors; (b) pharmaceutical compositions (comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.

Abstract: This invention relates to: (a) compounds of formula Ia (with R1, R4 to R6, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-?-hydroxylase inhibitors; (b) pharmaceutical compositions (comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.

Abstract: This invention relates to: (a) compounds of formula I (with R1 to R5 and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-?-hydroxylase inhibitors; (b) pharmaceutical compositions comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.

Abstract: This invention relates to: (a) compounds of formula Ia (with R1, R4 to R6, n and A as defined herein) and pharmaceutically acceptable salts or solvates thereof that are useful as dopamine-?-hydroxylase inhibitors; (b) pharmaceutical compositions (comprising such compounds, salts or solvates; (c) the use of such compounds, salts or solvates in therapy; (d) therapeutic methods of treatment using such compounds, salts or solvates; and (e) processes and intermediates useful for the synthesis of such compounds.

Abstract: A method for wind power curtailment optimization comprises calculating the power flow for a power network for the day-ahead; calculating a contingency analysis for the power network for the day-ahead, comprising forecasted power generation, power consumption and topology of said power network, together with a set of contingency scenarios; calculating a sensitivity factor of a power flow for each power network branch to a power injection by each wind power plant, wherein the sensitivity factor is calculated only for the periods of time of the day-ahead for which overloaded branches have been detected during the solving of the power flow or during the solving of the contingency analysis; selecting a subset of the wind power plants having at least one sensitivity factor above a predetermined threshold as curtailment candidates; and calculating the wind power curtailment restricted to the selected subset of wind power plants.

Abstract: A method for wind power curtailment optimization comprises calculating the power flow for a power network for the day-ahead; calculating a contingency analysis for the power network for the day-ahead, comprising forecasted power generation, power consumption and topology of said power network, together with a set of contingency scenarios; calculating a sensitivity factor of a power flow for each power network branch to a power injection by each wind power plant, wherein the sensitivity factor is calculated only for the periods of time of the day-ahead for which overloaded branches have been detected during the solving of the power flow or during the solving of the contingency analysis; selecting a subset of the wind power plants having at least one sensitivity factor above a predetermined threshold as curtailment candidates; and calculating the wind power curtailment restricted to the selected subset of wind power plants.

Abstract: A compound having Formula I: wherein: R1 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R2 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R3 is C1-4 alkyl; R4 is aryl which is substituted with a group selected from OSO2NH2, NHCONH2, NHSO2NH2, NHSO2C1-4 alkyl and CONH2; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; provided that the compound is not N-(1-benzylpiperidin-4-yl)-N-methyl-4-(4-(sulfamoylamino)phenyl)-1H-imidazole-1-carboxamide or N-(1-benzylpiperidin-4-yl)-N-methyl-4-(3-(methyl sulfonamido)phenyl)-1H-imidazole-1-carboxamide. The compound may be used as an inhibitor of fatty acid amide hydrolase.

Abstract: The present invention relates to a process and device RIM involving a mixing chamber (1) with opposing injectors (2, 3). The efficiency is maximized through the operation in flow regimes with very strong mixing dynamics, which is assured by means of the introduction of schemes to: detect the flow regime within the mixing chamber, through the dynamic pressure measurement upstream of the injectors (2, 3), using means (5); and/or impose a chaotic flow regime, through the pulsation of the opposed jets, using means (6). Alterations in design, comparatively to the traditional geometries, are also proposed, concerning: the mixing chamber (1), being foreseen a prismatic rectangular chamber; the injectors (2, 3), being foreseen elongated injectors; and even the scheme of injection of the materials, using a third injector (4).

Abstract: The present invention relates to a process and device RIM involving a mixing chamber (1) with opposing injectors (2, 3). The efficiency is maximised through the operation in flow regimes with very strong mixing dynamics, which is assured by means of the introduction of schemes to: detect the flow regime within the mixing chamber, through the dynamic pressure measurement upstream of the injectors (2, 3), using means (5); and/or impose a chaotic flow regime, through the pulsation of the opposed jets, using means (6). Alterations in design, comparatively to the traditional geometries, are also proposed, concerning: the mixing chamber (1), being foreseen a prismatic rectangular chamber; the injectors (2, 3), being foreseen elongated injectors; and even the scheme of injection of the materials, using a third injector (4).